| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Imiquimod 3.75% |
| Brand | Zyclara® |
| Indication | For topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate. |
| Assessment Process | |
| Rapid review commissioned | 10/09/2013 |
| Rapid review completed | 18/09/2013 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
